Philips Ultrasound Options Cleared for Covid-19

FDA has cleared a Royal Philips 510(k) for ultrasound options for managing Covid-19-related lung and cardiac complications. “Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating Covid-19 patients due to their imaging capabilities, portability and ease of disinfection,” the company says. The regulatory clearance permits Philips to provide detailed, practical guidance to support clinicians using its systems and software for Covid-19 patients. The new guidance highlights specific presets, transducers, quantification tools and other capabilities available on Philips' ultrasound systems that are relevant in assessing and managing COVID-19-related lung and cardiac complications, the company says. The clearance applies to Philips ultrasound systems including the EPIQ series, Affiniti series, Lumify, CX50 and Sparq diagnostic ultrasound systems.